Efficacy and safety of disitamab vedotin (RC48) combined with toripalimab as adjuvant therapy after radical surgery for patients with HER2-overexpression upper tract urothelial cancer (UTUC): A single-arm, prospective, phase 2 clinical trial.

医学 尿路上皮癌 佐剂 泌尿科 前瞻性队列研究 辅助治疗 肿瘤科 外科 内科学 癌症 膀胱癌
作者
Shouyong Liu,Miao He,Song Xue,Feng Xu,Zhenyu Xu,Dian Fu,Haowei He,Wenquan Zhou,Jingping Ge,Le Qu
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (16_suppl): 4590-4590 被引量:1
标识
DOI:10.1200/jco.2025.43.16_suppl.4590
摘要

4590 Background: UTUC is rare and highly aggressive. The prognosis is poor, especially for high-risk patients, even after radical surgery. Adjuvant chemotherapy is the standard therapy, but with limited efficacy, indicating a need for more effective regimens. RC48, an anti-HER2 antibody-drug conjugate, combined with toripalimab, an anti-PD-1 monoclonal antibody, has shown promising results in locally advanced or metastatic urothelial carcinoma (C014 trial). We evaluate the efficacy and safety of RC48 combined with toripalimab as adjuvant therapy for patients with HER2 IHC 2+/3+ UTUC after radical surgery. Methods: This is a single-arm, prospective, phase 2 clinical trial (NCT05917158). Eligible criteria were patients with histologically confirmed HER2 IHC 2+/3+ UTUC after radical surgery and were staged as T2-4NanyM0 or TanyN1-2M0, with no prior neoadjuvant therapy. The intervention was intravenous RC48 (2 mg/kg) combined with toripalimab (3 mg/kg) triweekly for 6 cycles, followed by toripalimab (3 mg/kg) triweekly for up to 1 year. The primary endpoint was DFS, and the secondary endpoints were OS, safety, and MRD analysis. Results: 45 patients (35 males [77.8%], median age 68 years [IQR 58-71]) were enrolled. The patients were staged as: 43 (95.6%) in II, 1 (2.2%) in III, and 1 (2.2%) in IV. All patients were HER2-overexpression (80% in IHC 2+, 20% in IHC 3+). 25 patients (55.6%) met cisplatin-ineligibility. By the data cutoff date on January 14, 2025, the median follow-up time was 12.2 months (IQR 6.7-17.6). 4 relapses occurred: 2 in lymph nodes, 1 in the prostate, and 1 in lymph nodes and the bladder. The 1-year DFS rate was 90.0%, and the median DFS has not been reached. All patients experienced treatment-related adverse events (TRAEs). The most common TRAEs were hypoesthesia (51.1%), increased blood glucose (48.9%), anemia (46.7%), increased creatinine (46.7%), and hypertriglyceridemia (46.7%). TRAEs of grade ≥3 occurred in 20% of patients. 8.9% of patients experienced immune-related adverse events, including rash and hypothyroidism. Among the patients, 16 (35.6%) completed treatment, 19 (42.2%) were still undergoing intervention, 4 (8.9%) discontinued therapy due to TRAEs: 1 with hypoesthesia, 1 with lymphocytopenia and hypoesthesia, 1 with nausea, vomiting, and decreased appetite, and 1 with pruritus and diarrhea, and 2 withdrew after completing 4 cycles of combined regimen due to personal reasons. No deaths occurred during the follow-up period. Conclusions: This is the first prospective clinical trial evaluating the efficacy and safety of the new adjuvant regimen for patients with HER2-IHC 2+/3+ UTUC. It showed promising DFS outcomes and a manageable safety profile, highlighting its potential as a new adjuvant therapy in patients with HER2-IHC 2+/3+ UTUC. Clinical trial information: NCT05917158 .

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小蘑菇的应助被lllzy采纳,获得10
刚刚
小马甲的应助被拼搏飞柏采纳,获得10
刚刚
科研通AI6.4的应助被雪山大地采纳,获得10
1秒前
wg发布了新的文献求助10
1秒前
JJ发布了新的文献求助10
2秒前
lx的应助被饱满的醉冬采纳,获得10
2秒前
369ninja发布了新的文献求助10
2秒前
2秒前
宁静致远发布了新的文献求助10
2秒前
向日葵发布了新的文献求助10
3秒前
3秒前
4秒前
非洲小泼猴完成签到,获得积分10
5秒前
lrh发布了新的文献求助10
5秒前
5秒前
小小爻完成签到,获得积分20
5秒前
Arain456完成签到 ,获得积分10
5秒前
5秒前
5秒前
风吹麦浪的应助被酷炫绍辉采纳,获得10
6秒前
赘婿的应助被JJ采纳,获得10
6秒前
魔幻的问蕊完成签到 ,获得积分10
7秒前
充电宝的应助被Lud030采纳,获得10
7秒前
爆米花的应助被彭彭采纳,获得10
7秒前
7秒前
7秒前
WendyWen发布了新的文献求助10
7秒前
QQ发布了新的文献求助10
7秒前
傻子完成签到,获得积分10
8秒前
9秒前
huixing完成签到,获得积分10
9秒前
Xiaohuyan发布了新的文献求助10
9秒前
10秒前
LLLLLLLLLLLLL发布了新的文献求助10
11秒前
MYY发布了新的文献求助10
12秒前
AC发布了新的文献求助10
12秒前
Julian的应助被Yixin_Niu采纳,获得30
12秒前
靈喵喵发布了新的文献求助10
13秒前
Rick完成签到,获得积分20
16秒前
Auster发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165135
求助须知:如何正确求助?哪些是违规求助? 9558801
关于积分的说明 21747483
捐赠科研通 7755702
什么是DOI,文献DOI怎么找? 3428797
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473402